MERCADO DE MEDICAMENTOS DE INSULINA HUMANA: CRECIMIENTO, TENDENCIAS, IMPACTO DE COVID-19 Y PRONÓSTICOS (2022 - 2027)

El mercado está segmentado por tipo de producto (insulinas humanas tradicionales, insulinas basales o de acción prolongada, insulinas en bolo o de acción rápida, combinaciones de insulina e insulinas biosimilares) y geografía.

Instantánea del mercado

Human Insulin Drugs Market Overview
Study Period: 2016-2027
Base Year: 2021
Fastest Growing Market: North America
Largest Market: North America
CAGR: 4.19 %
Human Insulin Drugs Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Visión general del mercado

Se espera que el mercado de medicamentos de insulina humana registre una CAGR del 4,19% durante el período de pronóstico de 2020-2025 y se estima que alcance los 29,9 mil millones de dólares para 2025. La diabetes generalmente se considera una enfermedad relacionada con el estilo de vida. Con el tiempo, la incidencia de la enfermedad ha aumentado escandalosamente, con el aumento de la población en todo el mundo. Aproximadamente 100 millones de personas en todo el mundo necesitan insulina, incluidas todas las personas que padecen diabetes tipo 1 y entre el 10 y el 25 % de las personas con diabetes tipo 2. Aunque la insulina se ha utilizado en el tratamiento de la diabetes durante más de 90 años, a nivel mundial, más de la mitad de las personas que necesitan insulina hoy en día todavía no pueden pagarla ni acceder a ella. Las personas con diabetes tipo 1 necesitan terapia con insulina, que se enfoca en controlar los niveles de azúcar en la sangre, junto con la insulina, la dieta y el estilo de vida, para prevenir complicaciones.

Alcance del Informe

El estudio abarca los siguientes aspectos:

By Product Type
Basal or Long-acting Insulins (Value and Volume, 2012-2025)
Lantus (Insulin glargine)
Levemir (Insulin detemir)
Toujeo (Insulin glargine)
Tresiba (Insulin degludec)
Basaglar (Insulin glargine)
Bolus or Fast-acting Insulins (Value and Volume, 2012-2025)
NovoRapid/Novolog (Insulin aspart)
Humalog (Insulin lispro)
Apidra (Insulin glulisine)
FIASP (Insulin aspart)
Admelog (Insulin lispro)
Traditional Human Insulins (Value and Volume, 2012-2025)
Novolin/Actrapid/Insulatard
Humulin
Insuman
Combination Insulins (Value and Volume, 2012-2025)
NovoMix (Biphasic Insulin aspart)
Ryzodeg (Insulin degludec/Insulin aspart)
Xultophy (Insulin degludec/Liraglutide)
Soliqua/Suliqua (Insulin glargine/Lixisenatide)
Biosimilar Insulins (Value and Volume, 2012-2025)
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Geography
North America
United States (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Canada (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of North America (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Europe
France (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Germany (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Italy (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Spain (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
United Kingdom (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Russia (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of Europe (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Latin America
Mexico (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Brazil (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of Latin America (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Asia-Pacific
Japan (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
South Korea (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
China (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
India (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Australia (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Vietnam (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Malaysia (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Indonesia (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Philippines (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Thailand (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of Asia-Pacific (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Middle-East and Africa
Saudi Arabia (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Iran (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Egypt (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Oman (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
South Africa (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of Middle-East and Africa (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins

Report scope can be customized per your requirements. Click here.

Tendencias clave del mercado

La creciente prevalencia de la diabetes impulsa el mercado

Aproximadamente, 100 millones de personas en todo el mundo necesitan insulina, incluidas todas las personas que padecen diabetes tipo 1 y entre el 10 y el 25 % de las personas con diabetes tipo 2. Aunque la insulina se ha utilizado en el tratamiento de la diabetes en todo el mundo durante más de 90 años, más de la mitad de la población que necesita insulina en la actualidad, todavía no puede pagarla ni acceder a ella. Las personas con diabetes tipo 1 necesitan terapia con insulina, y el tratamiento se enfoca en controlar los niveles de azúcar en la sangre con insulina, dieta y estilo de vida para prevenir complicaciones. La I+D en los segmentos de insulina aumenta año tras año, ya que los investigadores intentan sacar la mejor molécula para el uso de los pacientes, reducir al máximo los efectos secundarios y aumentar su eficiencia. Por lo tanto, es probable que la creciente prevalencia de la obesidad y la diabetes en todo el mundo aumente considerablemente la demanda de insulina,

Human Insulin Drugs Market Key Trends

Norteamérica domina el mercado

América del Norte domina el mercado mundial de insulina humana, especialmente Estados Unidos, debido a la alta prevalencia de diabetes en la región debido a un estilo de vida sedentario. El factor costo es la principal preocupación en los Estados Unidos, donde casi el 50% de los ingresos por insulina para los fabricantes provienen del propio país. Estados Unidos representa las mayores ventas de insulina de acción prolongada, Lantus, en todo el mundo. La mayoría de las empresas de fabricación de medicamentos para la diabetes consideran al país como un mercado crítico para mejorar las ventas globales en general. Lantus es la insulina basal más administrada en todo el mundo y representa una participación dominante en el mercado estadounidense. Se espera que el mercado tradicional de medicamentos de insulina humana de América del Norte crezca durante el período de pronóstico, debido a su asequibilidad económica para los pacientes. Humulin tiene la cuota de mercado más alta, seguida de Novolin. No hay competidores genéricos para el mercado tradicional de medicamentos de insulina humana de América del Norte en los Estados Unidos.

Human Insulin Drugs Market Growth by Region

Panorama competitivo

El mercado global de insulina humana está altamente consolidado con tres fabricantes principales que tienen presencia en el mercado global y los fabricantes restantes se limitan a los otros fabricantes locales o específicos de la región. Las fusiones y adquisiciones que ocurrieron entre los jugadores en el pasado reciente han ayudado a las empresas a fortalecer su presencia en el mercado. Eli Lilly y Boehringer Ingelheim juntos tienen una alianza para desarrollar y comercializar Basaglar (insulina glargina).

Insulinas en desarrollo:

Novo Nordisk está desarrollando una primera insulina de acción prolongada una vez a la semana (LAI287) que actualmente se encuentra en la fase 2. La insulina está indicada para pacientes con diabetes tipo 1 y tipo 2. Eli Lilly está desarrollando una insulina Fc de acción prolongada (LY3209590) . La "insulina basal-Fc" es una molécula grande compuesta por insulina modificada fusionada con un dominio Fc diseñado para proporcionar un perfil basal de acción prolongada. LY3209590 está en estudio para el tratamiento de la diabetes.

Los medicamentos de insulina oral impulsarán el mercado:

Biocon está desarrollando Insulin Tregopil , un comprimido oral de insulina prandial, para el tratamiento de la diabetes mellitus tipo 1 y tipo 2. La insulina oral de acción rápida podría mejorar el control de la glucosa posprandial con efectos secundarios reducidos y una mayor adherencia, lo que promete transformar el manejo de la DT1. Oramed Pharmaceuticals Inc., una compañía farmacéutica en etapa clínica, enfocada en el desarrollo de sistemas de administración oral de medicamentos, está trabajando para lanzar al mercado el primer producto de insulina oral, proporcionando así un método más conveniente, efectivo y seguro para administración de terapia con insulina.

LIST OF TABLES AND FIGURES

 

LIST OF TABLES

1 Global Human Insulin Drugs Market: Revenue in USD million, by Product Type, 2012 - 2024
2 Global Human Insulin Drugs Market: Revenue in USD million, by Basal or Long-acting Insulins, 2012-2024
3 Global Human Insulin Drugs Market: Revenue in USD million, by Bolus or Fast-acting Insulins, 2012-2024
4 Global Human Insulin Drugs Market: Revenue in USD million, by Traditional Human Insulins, 2012-2024
5 Global Human Insulin Drugs Market: Revenue in USD million, by Combination Insulins, 2012-2024
6 Global Human Insulin Drugs Market: Revenue in USD million, by Biosimilar Insulins, 2012-2024
7 Global Human Insulin Drugs Market: Revenue in USD million, by Geography, 2012-2024
8 Global Human Insulin Drugs Market: Revenue in USD million, by North America, 2012-2024
9 Global Human Insulin Drugs Market: Revenue in USD million, by United States, by Segmentation, 2012-2024
10 Global Human Insulin Drugs Market: Revenue in USD million, by Canada, by Segmentation, 2012-2024
11 Global Human Insulin Drugs Market: Revenue in USD million, by Rest of North America, by Segmentation, 2012-2024
12 Global Human Insulin Drugs Market: Revenue in USD million, by Europe, 2012-2024
13 Global Human Insulin Drugs Market: Revenue in USD million, by United Kingdom, by Segmentation, 2012-2024
14 Global Human Insulin Drugs Market: Revenue in USD million, by Germany, by Segmentation, 2012-2024
15 Global Human Insulin Drugs Market: Revenue in USD million, by France, by Segmentation, 2012-2024
16 Global Human Insulin Drugs Market: Revenue in USD million, by Italy, by Segmentation, 2012-2024
17 Global Human Insulin Drugs Market: Revenue in USD million, by Spain, by Segmentation, 2012-2024
18 Global Human Insulin Drugs Market: Revenue in USD million, by Russia, by Segmentation, 2012-2024
19 Global Human Insulin Drugs Market: Revenue in USD million, by Rest of Europe, by Segmentation, 2012-2024
20 Global Human Insulin Drugs Market: Revenue in USD million, by Latin America, 2012-2024
21 Global Human Insulin Drugs Market: Revenue in USD million, by Mexico, by Segmentation, 2012-2024
22 Global Human Insulin Drugs Market: Revenue in USD million, by Brazil, by Segmentation, 2012-2024
23 Global Human Insulin Drugs Market: Revenue in USD million, by Rest of Latin America, by Segmentation, 2012-2024
24 Global Human Insulin Drugs Market: Revenue in USD million, by Asia-Pacific, 2012-2024
25 Global Human Insulin Drugs Market: Revenue in USD million, by Japan, by Segmentation, 2012-2024
26 Global Human Insulin Drugs Market: Revenue in USD million, by South Korea, by Segmentation, 2012-2024
27 Global Human Insulin Drugs Market: Revenue in USD million, by China, by Segmentation, 2012-2024
28 Global Human Insulin Drugs Market: Revenue in USD million, by India, by Segmentation, 2012-2024
29 Global Human Insulin Drugs Market: Revenue in USD million, by Australia, by Segmentation, 2012-2024
30 Global Human Insulin Drugs Market: Revenue in USD million, by Vietnam, by Segmentation, 2012-2024
31 Global Human Insulin Drugs Market: Revenue in USD million, by Malaysia, by Segmentation, 2012-2024
32 Global Human Insulin Drugs Market: Revenue in USD million, by Indonesia, by Segmentation, 2012-2024
33 Global Human Insulin Drugs Market: Revenue in USD million, by Philippines, by Segmentation, 2012-2024
34 Global Human Insulin Drugs Market: Revenue in USD million, by Thailand, by Segmentation, 2012-2024
35 Global Human Insulin Drugs Market: Revenue in USD million, by Rest of Asia-Pacific, by Segmentation, 2012-2024
36 Global Human Insulin Drugs Market: Revenue in USD million, by Middle East and Africa, 2012-2024
37 Global Human Insulin Drugs Market: Revenue in USD million, by Saudi Arabia, by Segmentation, 2012-2024
38 Global Human Insulin Drugs Market: Revenue in USD million, by Iran, by Segmentation, 2012-2024
39 Global Human Insulin Drugs Market: Revenue in USD million, by Egypt, by Segmentation, 2012-2024
40 Global Human Insulin Drugs Market: Revenue in USD million, by Oman, by Segmentation, 2012-2024
41 Global Human Insulin Drugs Market: Revenue in USD million, by South Africa, by Segmentation, 2012-2024
42 Global Human Insulin Drugs Market: Revenue in USD million, by Rest of Middle and Africa, by Segmentation, 2012-2024
43 Global Human Insulin Drugs Market: Revenue in USD million, by Market Indicators, 2012-2024

 

LIST OF FIGURES

1 Global Human Insulin Drugs Market, Revenue in USD million, 2012-2024
2 Global Countries Diabetes Population 2012-2024
3 Global Countries with High Obese Population, 2018
4 Global Human Insulin Drugs Market: Revenue in USD million, by Basal or Long-acting Insulins, 2012-2024
5 Global Human Insulin Drugs Market: Revenue in USD million, by Bolus or Fast-acting Insulins, 2012-2024
6 Global Human Insulin Drugs Market: Revenue in USD million, by Traditional Human Insulins, 2012-2024
7 Global Human Insulin Drugs Market: Revenue in USD million, by Combination Insulins, 2012-2024
8 Global Human Insulin Drugs Market: Revenue in USD million, by Biosimilar Insulins, 2012-2024
9 Global Human Insulin Drugs Market: Revenue in USD million, United States, 2012-2024
10 Global Human Insulin Drugs Market: Revenue in USD million, Canada, 2012-2024
11 Global Human Insulin Drugs Market: Revenue in USD million, Rest of North America, 2012-2024
12 Global Human Insulin Drugs Market: Revenue in USD million, United Kingdom, 2012-2024
13 Global Human Insulin Drugs Market: Revenue in USD million, Germany, 2012-2024
14 Global Human Insulin Drugs Market: Revenue in USD million, France, 2012-2024
15 Global Human Insulin Drugs Market: Revenue in USD million, Italy, 2012-2024
16 Global Human Insulin Drugs Market: Revenue in USD million, Spain, 2012-2024
17 Global Human Insulin Drugs Market: Revenue in USD million, Russia, 2012-2024
18 Global Human Insulin Drugs Market: Revenue in USD million, Rest of Europe, 2012-2024
19 Global Human Insulin Drugs Market: Revenue in USD million, Japan, 2012-2024
20 Global Human Insulin Drugs Market: Revenue in USD million, South Korea, 2012-2024
21 Global Human Insulin Drugs Market: Revenue in USD million, China, 2012-2024
22 Global Human Insulin Drugs Market: Revenue in USD million, India, 2012-2024
23 Global Human Insulin Drugs Market: Revenue in USD million, Australia, 2012-2024
24 Global Human Insulin Drugs Market: Revenue in USD million, Vietnam, 2012-2024
25 Global Human Insulin Drugs Market: Revenue in USD million, Malaysia, 2012-2024
26 Global Human Insulin Drugs Market: Revenue in USD million, Indonesia,  2012-2024
27 Global Human Insulin Drugs Market: Revenue in USD million, Philippines, 2012-2024
28 Global Human Insulin Drugs Market: Revenue in USD million, Thailand, 2012-2024
29 Global Human Insulin Drugs Market: Revenue in USD million, Rest of Asia-Pacific, 2012-2024
30 Global Human Insulin Drugs Market: Revenue in USD million, Saudi Arabia, 2012-2024
31 Global Human Insulin Drugs Market: Revenue in USD million, Iran, 2012-2024
32 Global Human Insulin Drugs Market: Revenue in USD million, Egypt, 2012-2024
33 Global Human Insulin Drugs Market: Revenue in USD million, Oman, 2012-2024
34 Global Human Insulin Drugs Market: Revenue in USD million, South Africa, 2012-2024
35 Global Human Insulin Drugs Market: Revenue in USD million, Rest of Middle and Africa, 2012-2024
36 Novo Nordisk AS Diabetes Care Revenue in USD million, 2016-2018
37 Novo Nordisk AS Diabetes Care Revenue Breakdown -  By Division (2018)
38 Novo Nordisk AS Diabetes Care Revenue Breakdown -  By Geographic Segment (2018)
39 Sanofi Aventis Revenue in USD million, 2016-2018
40 Sanofi Aventis Revenue Breakdown -  By Division (2018)
41 Sanofi Aventis Revenue Breakdown -  By Geographic Segment (2018)
42 Eli Lilly Revenue in USD million, 2016-2018
43 Eli Lilly Revenue Breakdown -  By Division (2018)
44 Eli Lilly Revenue Breakdown -  By Geographic Segment (2018)
45 Biocon Revenue in USD million, 2016-2018
46 Biocon Revenue Breakdown -  By Division (2018)
47 Biocon Revenue Breakdown -  By Geographic Segment (2018)
48 Pfizer Revenue in USD million, 2016-2018
49 Pfizer Revenue Breakdown -  By Division (2018)
50 Pfizer Revenue Breakdown -  By Geographic Segment (2018)
51 Julphar Revenue in USD million, 2016-2018
52 Julphar Revenue Breakdown -  By Division (2018)
53 Julphar Revenue Breakdown -  By Geographic Segment (2018)
54 Exir Revenue in USD million, 2016-2018
55 Exir Revenue Breakdown -  By Division (2018)
56 Exir Revenue Breakdown -  By Geographic Segment (2018)
57 Sedico Revenue in USD million, 2016-2018
58 Sedico Revenue Breakdown -  By Division (2018)
59 Sedico Revenue Breakdown -  By Geographic Segment (2018)
60 Wockhardt Revenue in USD million, 2016-2018
61 Wockhardt Revenue Breakdown -  By Division (2018)
62 Wockhardt Revenue Breakdown -  By Geographic Segment (2018)
63 Company Share Analysis (2018)

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product Type

      1. 5.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2025)

        1. 5.1.1.1 Lantus (Insulin glargine)

        2. 5.1.1.2 Levemir (Insulin detemir)

        3. 5.1.1.3 Toujeo (Insulin glargine)

        4. 5.1.1.4 Tresiba (Insulin degludec)

        5. 5.1.1.5 Basaglar (Insulin glargine)

      2. 5.1.2 Bolus or Fast-acting Insulins (Value and Volume, 2012-2025)

        1. 5.1.2.1 NovoRapid/Novolog (Insulin aspart)

        2. 5.1.2.2 Humalog (Insulin lispro)

        3. 5.1.2.3 Apidra (Insulin glulisine)

        4. 5.1.2.4 FIASP (Insulin aspart)

        5. 5.1.2.5 Admelog (Insulin lispro)

      3. 5.1.3 Traditional Human Insulins (Value and Volume, 2012-2025)

        1. 5.1.3.1 Novolin/Actrapid/Insulatard

        2. 5.1.3.2 Humulin

        3. 5.1.3.3 Insuman

      4. 5.1.4 Combination Insulins (Value and Volume, 2012-2025)

        1. 5.1.4.1 NovoMix (Biphasic Insulin aspart)

        2. 5.1.4.2 Ryzodeg (Insulin degludec/Insulin aspart)

        3. 5.1.4.3 Xultophy (Insulin degludec/Liraglutide)

        4. 5.1.4.4 Soliqua/Suliqua (Insulin glargine/Lixisenatide)

      5. 5.1.5 Biosimilar Insulins (Value and Volume, 2012-2025)

        1. 5.1.5.1 Insulin Glargine Biosimilars

        2. 5.1.5.2 Human Insulin Biosimilars

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States (Value and Volume, 2012-2025)

          1. 5.2.1.1.1 Basal or Long-acting Insulins

          2. 5.2.1.1.2 Bolus or Fast-acting Insulins

          3. 5.2.1.1.3 Traditional Human Insulins

          4. 5.2.1.1.4 Combination Insulins

          5. 5.2.1.1.5 Biosimilar Insulins

        2. 5.2.1.2 Canada (Value and Volume, 2012-2025)

          1. 5.2.1.2.1 Basal or Long-acting Insulins

          2. 5.2.1.2.2 Bolus or Fast-acting Insulins

          3. 5.2.1.2.3 Traditional Human Insulins

          4. 5.2.1.2.4 Combination Insulins

          5. 5.2.1.2.5 Biosimilar Insulins

        3. 5.2.1.3 Rest of North America (Value and Volume, 2012-2025)

          1. 5.2.1.3.1 Basal or Long-acting Insulins

          2. 5.2.1.3.2 Bolus or Fast-acting Insulins

          3. 5.2.1.3.3 Traditional Human Insulins

          4. 5.2.1.3.4 Combination Insulins

          5. 5.2.1.3.5 Biosimilar Insulins

      2. 5.2.2 Europe

        1. 5.2.2.1 France (Value and Volume, 2012-2025)

          1. 5.2.2.1.1 Basal or Long-acting Insulins

          2. 5.2.2.1.2 Bolus or Fast-acting Insulins

          3. 5.2.2.1.3 Traditional Human Insulins

          4. 5.2.2.1.4 Combination Insulins

          5. 5.2.2.1.5 Biosimilar Insulins

        2. 5.2.2.2 Germany (Value and Volume, 2012-2025)

          1. 5.2.2.2.1 Basal or Long-acting Insulins

          2. 5.2.2.2.2 Bolus or Fast-acting Insulins

          3. 5.2.2.2.3 Traditional Human Insulins

          4. 5.2.2.2.4 Combination Insulins

          5. 5.2.2.2.5 Biosimilar Insulins

        3. 5.2.2.3 Italy (Value and Volume, 2012-2025)

          1. 5.2.2.3.1 Basal or Long-acting Insulins

          2. 5.2.2.3.2 Bolus or Fast-acting Insulins

          3. 5.2.2.3.3 Traditional Human Insulins

          4. 5.2.2.3.4 Combination Insulins

          5. 5.2.2.3.5 Biosimilar Insulins

        4. 5.2.2.4 Spain (Value and Volume, 2012-2025)

          1. 5.2.2.4.1 Basal or Long-acting Insulins

          2. 5.2.2.4.2 Bolus or Fast-acting Insulins

          3. 5.2.2.4.3 Traditional Human Insulins

          4. 5.2.2.4.4 Combination Insulins

          5. 5.2.2.4.5 Biosimilar Insulins

        5. 5.2.2.5 United Kingdom (Value and Volume, 2012-2025)

          1. 5.2.2.5.1 Basal or Long-acting Insulins

          2. 5.2.2.5.2 Bolus or Fast-acting Insulins

          3. 5.2.2.5.3 Traditional Human Insulins

          4. 5.2.2.5.4 Combination Insulins

          5. 5.2.2.5.5 Biosimilar Insulins

        6. 5.2.2.6 Russia (Value and Volume, 2012-2025)

          1. 5.2.2.6.1 Basal or Long-acting Insulins

          2. 5.2.2.6.2 Bolus or Fast-acting Insulins

          3. 5.2.2.6.3 Traditional Human Insulins

          4. 5.2.2.6.4 Combination Insulins

          5. 5.2.2.6.5 Biosimilar Insulins

        7. 5.2.2.7 Rest of Europe (Value and Volume, 2012-2025)

          1. 5.2.2.7.1 Basal or Long-acting Insulins

          2. 5.2.2.7.2 Bolus or Fast-acting Insulins

          3. 5.2.2.7.3 Traditional Human Insulins

          4. 5.2.2.7.4 Combination Insulins

          5. 5.2.2.7.5 Biosimilar Insulins

      3. 5.2.3 Latin America

        1. 5.2.3.1 Mexico (Value and Volume, 2012-2025)

          1. 5.2.3.1.1 Basal or Long-acting Insulins

          2. 5.2.3.1.2 Bolus or Fast-acting Insulins

          3. 5.2.3.1.3 Traditional Human Insulins

          4. 5.2.3.1.4 Combination Insulins

          5. 5.2.3.1.5 Biosimilar Insulins

        2. 5.2.3.2 Brazil (Value and Volume, 2012-2025)

          1. 5.2.3.2.1 Basal or Long-acting Insulins

          2. 5.2.3.2.2 Bolus or Fast-acting Insulins

          3. 5.2.3.2.3 Traditional Human Insulins

          4. 5.2.3.2.4 Combination Insulins

          5. 5.2.3.2.5 Biosimilar Insulins

        3. 5.2.3.3 Rest of Latin America (Value and Volume, 2012-2025)

          1. 5.2.3.3.1 Basal or Long-acting Insulins

          2. 5.2.3.3.2 Bolus or Fast-acting Insulins

          3. 5.2.3.3.3 Traditional Human Insulins

          4. 5.2.3.3.4 Combination Insulins

          5. 5.2.3.3.5 Biosimilar Insulins

      4. 5.2.4 Asia-Pacific

        1. 5.2.4.1 Japan (Value and Volume, 2012-2025)

          1. 5.2.4.1.1 Basal or Long-acting Insulins

          2. 5.2.4.1.2 Bolus or Fast-acting Insulins

          3. 5.2.4.1.3 Traditional Human Insulins

          4. 5.2.4.1.4 Combination Insulins

          5. 5.2.4.1.5 Biosimilar Insulins

        2. 5.2.4.2 South Korea (Value and Volume, 2012-2025)

          1. 5.2.4.2.1 Basal or Long-acting Insulins

          2. 5.2.4.2.2 Bolus or Fast-acting Insulins

          3. 5.2.4.2.3 Traditional Human Insulins

          4. 5.2.4.2.4 Combination Insulins

          5. 5.2.4.2.5 Biosimilar Insulins

        3. 5.2.4.3 China (Value and Volume, 2012-2025)

          1. 5.2.4.3.1 Basal or Long-acting Insulins

          2. 5.2.4.3.2 Bolus or Fast-acting Insulins

          3. 5.2.4.3.3 Traditional Human Insulins

          4. 5.2.4.3.4 Combination Insulins

          5. 5.2.4.3.5 Biosimilar Insulins

        4. 5.2.4.4 India (Value and Volume, 2012-2025)

          1. 5.2.4.4.1 Basal or Long-acting Insulins

          2. 5.2.4.4.2 Bolus or Fast-acting Insulins

          3. 5.2.4.4.3 Traditional Human Insulins

          4. 5.2.4.4.4 Combination Insulins

          5. 5.2.4.4.5 Biosimilar Insulins

        5. 5.2.4.5 Australia (Value and Volume, 2012-2025)

          1. 5.2.4.5.1 Basal or Long-acting Insulins

          2. 5.2.4.5.2 Bolus or Fast-acting Insulins

          3. 5.2.4.5.3 Traditional Human Insulins

          4. 5.2.4.5.4 Combination Insulins

          5. 5.2.4.5.5 Biosimilar Insulins

        6. 5.2.4.6 Vietnam (Value and Volume, 2012-2025)

          1. 5.2.4.6.1 Basal or Long-acting Insulins

          2. 5.2.4.6.2 Bolus or Fast-acting Insulins

          3. 5.2.4.6.3 Traditional Human Insulins

          4. 5.2.4.6.4 Combination Insulins

          5. 5.2.4.6.5 Biosimilar Insulins

        7. 5.2.4.7 Malaysia (Value and Volume, 2012-2025)

          1. 5.2.4.7.1 Basal or Long-acting Insulins

          2. 5.2.4.7.2 Bolus or Fast-acting Insulins

          3. 5.2.4.7.3 Traditional Human Insulins

          4. 5.2.4.7.4 Combination Insulins

          5. 5.2.4.7.5 Biosimilar Insulins

        8. 5.2.4.8 Indonesia (Value and Volume, 2012-2025)

          1. 5.2.4.8.1 Basal or Long-acting Insulins

          2. 5.2.4.8.2 Bolus or Fast-acting Insulins

          3. 5.2.4.8.3 Traditional Human Insulins

          4. 5.2.4.8.4 Combination Insulins

          5. 5.2.4.8.5 Biosimilar Insulins

        9. 5.2.4.9 Philippines (Value and Volume, 2012-2025)

          1. 5.2.4.9.1 Basal or Long-acting Insulins

          2. 5.2.4.9.2 Bolus or Fast-acting Insulins

          3. 5.2.4.9.3 Traditional Human Insulins

          4. 5.2.4.9.4 Combination Insulins

          5. 5.2.4.9.5 Biosimilar Insulins

        10. 5.2.4.10 Thailand (Value and Volume, 2012-2025)

          1. 5.2.4.10.1 Basal or Long-acting Insulins

          2. 5.2.4.10.2 Bolus or Fast-acting Insulins

          3. 5.2.4.10.3 Traditional Human Insulins

          4. 5.2.4.10.4 Combination Insulins

          5. 5.2.4.10.5 Biosimilar Insulins

        11. 5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2025)

          1. 5.2.4.11.1 Basal or Long-acting Insulins

          2. 5.2.4.11.2 Bolus or Fast-acting Insulins

          3. 5.2.4.11.3 Traditional Human Insulins

          4. 5.2.4.11.4 Combination Insulins

          5. 5.2.4.11.5 Biosimilar Insulins

      5. 5.2.5 Middle-East and Africa

        1. 5.2.5.1 Saudi Arabia (Value and Volume, 2012-2025)

          1. 5.2.5.1.1 Basal or Long-acting Insulins

          2. 5.2.5.1.2 Bolus or Fast-acting Insulins

          3. 5.2.5.1.3 Traditional Human Insulins

          4. 5.2.5.1.4 Combination Insulins

          5. 5.2.5.1.5 Biosimilar Insulins

        2. 5.2.5.2 Iran (Value and Volume, 2012-2025)

          1. 5.2.5.2.1 Basal or Long-acting Insulins

          2. 5.2.5.2.2 Bolus or Fast-acting Insulins

          3. 5.2.5.2.3 Traditional Human Insulins

          4. 5.2.5.2.4 Combination Insulins

          5. 5.2.5.2.5 Biosimilar Insulins

        3. 5.2.5.3 Egypt (Value and Volume, 2012-2025)

          1. 5.2.5.3.1 Basal or Long-acting Insulins

          2. 5.2.5.3.2 Bolus or Fast-acting Insulins

          3. 5.2.5.3.3 Traditional Human Insulins

          4. 5.2.5.3.4 Combination Insulins

          5. 5.2.5.3.5 Biosimilar Insulins

        4. 5.2.5.4 Oman (Value and Volume, 2012-2025)

          1. 5.2.5.4.1 Basal or Long-acting Insulins

          2. 5.2.5.4.2 Bolus or Fast-acting Insulins

          3. 5.2.5.4.3 Traditional Human Insulins

          4. 5.2.5.4.4 Combination Insulins

          5. 5.2.5.4.5 Biosimilar Insulins

        5. 5.2.5.5 South Africa (Value and Volume, 2012-2025)

          1. 5.2.5.5.1 Basal or Long-acting Insulins

          2. 5.2.5.5.2 Bolus or Fast-acting Insulins

          3. 5.2.5.5.3 Traditional Human Insulins

          4. 5.2.5.5.4 Combination Insulins

          5. 5.2.5.5.5 Biosimilar Insulins

        6. 5.2.5.6 Rest of Middle-East and Africa (Value and Volume, 2012-2025)

          1. 5.2.5.6.1 Basal or Long-acting Insulins

          2. 5.2.5.6.2 Bolus or Fast-acting Insulins

          3. 5.2.5.6.3 Traditional Human Insulins

          4. 5.2.5.6.4 Combination Insulins

          5. 5.2.5.6.5 Biosimilar Insulins

  6. 6. MARKET INDICATORS

    1. 6.1 Type 1 Diabetes Population (2012-2025)

    2. 6.2 Type 2 Diabetes Population (2012-2025)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 COMPANY PROFILES

      1. 7.1.1 Novo Nordisk A/S

        1. 7.1.1.1 Overview

        2. 7.1.1.2 Products and Strategies

        3. 7.1.1.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.1.4 Ratio Analysis (5 Years)

        5. 7.1.1.5 Strength and Stability Analysis (5 Years)

        6. 7.1.1.6 Recent Developments

      2. 7.1.2 Sanofi S.A.

        1. 7.1.2.1 Overview

        2. 7.1.2.2 Products and Strategies

        3. 7.1.2.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.2.4 Ratio Analysis (5 Years)

        5. 7.1.2.5 Strength and Stability Analysis (5 Years)

        6. 7.1.2.6 Recent Developments

      3. 7.1.3 Eli Lilly and Company

        1. 7.1.3.1 Overview

        2. 7.1.3.2 Products and Strategies

        3. 7.1.3.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.3.4 Ratio Analysis (5 Years)

        5. 7.1.3.5 Strength and Stability Analysis (5 Years)

        6. 7.1.3.6 Recent Developments

      4. 7.1.4 Biocon Limited

        1. 7.1.4.1 Overview

        2. 7.1.4.2 Products and Strategies

        3. 7.1.4.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.4.4 Ratio Analysis (5 Years)

        5. 7.1.4.5 Strength and Stability Analysis (5 Years)

        6. 7.1.4.6 Recent Developments

      5. 7.1.5 Pfizer Inc.

        1. 7.1.5.1 Overview

        2. 7.1.5.2 Products and Strategies

        3. 7.1.5.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.5.4 Ratio Analysis (5 Years)

        5. 7.1.5.5 Strength and Stability Analysis (5 Years)

        6. 7.1.5.6 Recent Developments

      6. 7.1.6 Wockhardt

        1. 7.1.6.1 Overview

        2. 7.1.6.2 Products and Strategies

        3. 7.1.6.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.6.4 Ratio Analysis (5 Years)

        5. 7.1.6.5 Strength and Stability Analysis (5 Years)

        6. 7.1.6.6 Recent Developments

      7. 7.1.7 Julphar

        1. 7.1.7.1 Overview

        2. 7.1.7.2 Products and Strategies

        3. 7.1.7.3 Recent Developments

      8. 7.1.8 Exir

        1. 7.1.8.1 Overview

        2. 7.1.8.2 Products and Strategies

        3. 7.1.8.3 Recent Developments

      9. 7.1.9 Sedico

        1. 7.1.9.1 Overview

        2. 7.1.9.2 Products and Strategies

        3. 7.1.9.3 Recent Developments

    2. 7.2 COMPANY SHARE ANALYSIS

      1. 7.2.1 Novo Nordisk AS

      2. 7.2.2 Sanofi Aventis

      3. 7.2.3 Eli Lilly

      4. 7.2.4 Other Companies

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

Market size and volume of individual drugs provided for every country

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

El mercado de Drogas de insulina humana se estudia desde 2016 hasta 2027.

El mercado de medicamentos de insulina humana está creciendo a una CAGR del 4,19 % en los próximos 5 años.

América del Norte está creciendo a la CAGR más alta durante 2021-2026.

América del Norte tiene la participación más alta en 2021.

Novo Nordisk A/S, Eli Lilly and Company, Sanofi SA, Biocon Limited, Pfizer Inc. son las principales empresas que operan en el mercado de medicamentos de insulina humana.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!